6TG0
Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 21a
Summary for 6TG0
| Entry DOI | 10.2210/pdb6tg0/pdb |
| Descriptor | Epidermal growth factor receptor, ~{N}-[5-[4-[[4-[[1,3-bis(oxidanylidene)isoindol-2-yl]methyl]phenyl]amino]-7~{H}-pyrrolo[2,3-d]pyrimidin-5-yl]-2-(2-hydroxyethyloxy)phenyl]propanamide, 1,2-ETHANEDIOL, ... (5 entities in total) |
| Functional Keywords | her2, egfr, covalent inhibitors, transferase |
| Biological source | Homo sapiens (Human) |
| Total number of polymer chains | 2 |
| Total formula weight | 77713.55 |
| Authors | Niggenaber, J.,Mueller, M.P.,Rauh, D. (deposition date: 2019-11-14, release date: 2020-09-30, Last modification date: 2024-01-24) |
| Primary citation | Lategahn, J.,Hardick, J.,Grabe, T.,Niggenaber, J.,Jeyakumar, K.,Keul, M.,Tumbrink, H.L.,Becker, C.,Hodson, L.,Kirschner, T.,Klovekorn, P.,Ketzer, J.,Baumann, M.,Terheyden, S.,Unger, A.,Weisner, J.,Muller, M.P.,van Otterlo, W.A.L.,Bauer, S.,Rauh, D. Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach. J.Med.Chem., 63:11725-11755, 2020 Cited by PubMed Abstract: Mutated or amplified Her2 serves as a driver of non-small cell lung cancer or mediates resistance toward the inhibition of its family member epidermal growth factor receptor with small-molecule inhibitors. To date, small-molecule inhibitors targeting Her2 which can be used in clinical routine are lacking, and therefore, the development of novel inhibitors was undertaken. In this study, the well-established pyrrolopyrimidine scaffold was modified with structural motifs identified from a screening campaign with more than 1600 compounds, which were applied against wild-type Her2 and its mutant variant Her2-A775_G776insYVMA. The resulting inhibitors were designed to covalently target a reactive cysteine in the binding site of Her2 and were further optimized by means of structure-based drug design utilizing a set of obtained complex crystal structures. In addition, the analysis of binding kinetics and absorption, distribution, metabolism, and excretion parameters as well as mass spectrometry experiments and western blot analysis substantiated our approach. PubMed: 32931277DOI: 10.1021/acs.jmedchem.0c00870 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.5 Å) |
Structure validation
Download full validation report
